newdrugapprovals.org
CT 1812
CT-1812 Elayta Condition(s): Alzheimer’s Disease U.S. FDA Status: Alzheimer’s Disease (Phase 2) Company: Cognition Therapeutics Inc. CAS: 1802632-22-9 Chemical Formula: C24H33NO4S Molec…